Tanya M Laidlaw Selected Research

Inflammation (Inflammations)

1/2021	Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
1/2021	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
1/2021	Pathomechanisms of AERD-Recent Advances.
1/2020	NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.
1/2020	Biologics in chronic rhinosinusitis with nasal polyposis.
11/2019	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
1/2019	Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
1/2016	PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.
10/2015	Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
6/2015	Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya M Laidlaw Research Topics

Disease

29	Asthma (Bronchial Asthma) 01/2022 - 07/2012
21	Nasal Polyps (Nasal Polyp) 01/2022 - 04/2012
15	Inflammation (Inflammations) 01/2021 - 01/2010
12	Rhinosinusitis 01/2022 - 03/2014
8	Eosinophilia 01/2022 - 10/2013
8	Hypersensitivity (Allergy) 01/2022 - 09/2008
4	Polyps 11/2019 - 10/2015
3	Rhinorrhea 09/2018 - 03/2014
3	Pneumonia (Pneumonitis) 10/2013 - 01/2010
2	Anosmia 05/2022 - 01/2022
2	Chronic Cough 05/2022 - 12/2021
2	Cough 05/2022 - 12/2021
2	Aspirin-Induced Asthma 01/2020 - 01/2019
2	Respiratory Sounds (Crackle) 09/2018 - 03/2014
2	Bronchial Spasm 09/2018 - 11/2016
2	Respiratory Hypersensitivity 01/2017 - 07/2012
2	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 10/2015 - 07/2012
2	Vascular Remodeling 07/2012 - 01/2010
1	Chronic Urticaria 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Neurogenic Inflammation 12/2021
1	COVID-19 07/2021
1	Erythema 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Headache (Headaches) 01/2021
1	Hyperplasia 01/2021
1	Chronic Pain 01/2021
1	Opioid-Related Disorders (Opiate Addiction) 01/2021
1	Nasopharyngitis 01/2021
1	Pain (Aches) 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Back Pain (Backache) 01/2021
1	Rhinitis 01/2021
1	Exanthema (Rash) 10/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Infections 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Lung Injury 01/2020
1	Bronchiectasis 01/2020
1	Asthma and Nasal Polyps 12/2019
1	Atopic Dermatitis (Atopic Eczema) 11/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Hypophosphatemia 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Chest Pain (Chest Pains) 11/2016
1	Nose Diseases (Disease, Nose) 11/2016
1	Coronary Vasospasm (Coronary Artery Vasospasm) 11/2016

Drug/Important Bio-Agent (IBA)

41	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2022 - 04/2012
8	Pharmaceutical PreparationsIBA 01/2022 - 05/2017
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 05/2017
6	dupilumabIBA 01/2022 - 09/2019
6	Cyclooxygenase 1IBA 01/2020 - 07/2016
5	CytokinesIBA 12/2021 - 07/2012
5	EnzymesIBA 01/2021 - 01/2010
4	Dinoprostone (PGE2)FDA Link 01/2022 - 07/2012
4	ProstaglandinsIBA 01/2019 - 01/2010
3	Immunoglobulin E (IgE)IBA 01/2021 - 07/2014
3	Biological ProductsIBA 01/2021 - 01/2020
3	LeukotrienesIBA 10/2020 - 10/2013
3	Leukotriene E4IBA 01/2019 - 12/2013
3	Leukotriene C4IBA 10/2015 - 12/2013
3	Prostaglandins EIBA 06/2014 - 01/2010
2	Interleukin-13IBA 01/2021 - 11/2019
2	Monoclonal AntibodiesIBA 01/2021 - 11/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019 - 11/2016
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2017
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2015
2	AllergensIBA 06/2015 - 01/2010
2	Thromboxane Receptors (Thromboxane Receptor)IBA 06/2015 - 07/2012
1	Antitussive Agents (Antitussives)FDA Link 05/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Ion Channels (Ion Channel)IBA 12/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	mepolizumabIBA 01/2021
1	Small Cytoplasmic RNAIBA 01/2021
1	Opioid Analgesics (Opioids)IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	Interleukin-5 (Interleukin 5)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2020
1	InterferonsIBA 01/2020
1	InterleukinsIBA 11/2019
1	DexpramipexoleIBA 01/2019
1	Cyclooxygenase InhibitorsIBA 01/2019
1	Investigational DrugsIBA 01/2019
1	GlucocorticoidsIBA 01/2017
1	Methacholine Chloride (Methacholine)FDA Link 01/2017
1	Imatinib Mesylate (Gleevec)FDA Link 01/2017
1	Tryptases (Tryptase)IBA 01/2017
1	Thymic Stromal LymphopoietinIBA 01/2016
1	Group V Phospholipases A2IBA 01/2016
1	prostaglandin R2 D-isomerase (prostaglandin D2 synthase)IBA 01/2016
1	Phospholipases A2 (Phospholipase A2)IBA 01/2016
1	CarboxypeptidasesIBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016

Therapy/Procedure

9	Therapeutics 05/2022 - 07/2012
2	Drug Therapy (Chemotherapy) 05/2022 - 09/2008
1	Biological Therapy 01/2020
1	Drug Tapering 11/2016